Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | ESH CML highlights: the role of metabolism in CML & novel methods to predict response to treatment

Daniela Krause • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Daniela Krause, MD, Georg-Speyer-Haus, Goethe University, Frankfurt, Germany, shares some of her highlights from the ESH CML meeting, discussing the role of metabolism in chronic myeloid leukemia (CML) and the possibility to predict treatment outcomes using markers identified with single-cell technologies and by measuring residual disease in granulocytes, and highlighting a novel promising combination strategy. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Support from Merck KGaA

More from Daniela Krause

1:18
The role of the bone marrow microenvironment in initiation and progression of CML
Daniela Krause • 22 Oct 2022
1:00
The role of FLOT2 in CML progression & how it differs from AML
Daniela Krause • 22 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals